WeBD.Tokyo
  • Home
  • Insights
  • About
  • Contact
  • cdmo.jp
  • LinkedIn

Japan Market Entry

Japan Market Entry

When Yes Means No: Decoding Japanese Tatemae in Pharma Business

When “Yes” Means No: Decoding Japanese Tatemae in Pharma Business At BioJapan, did every meeting feel like a success — until the silence came afterward?You’re not alone. Many Western pharma executives walk out of Yokohama believing they’ve gained traction, only to face weeks of polite quiet. The reason isn’t lack Read more

By md, 5 monthsOctober 17, 2025 ago

Recent Posts

  • Launching cdmo.jp — A Japan-first platform to showcase differentiated CDMO technologies
  • When Yes Means No: Decoding Japanese Tatemae in Pharma Business
  • BioJapan 2025: A Gentle Reminder on CDMO & Biotech Sales —Why Trust Matters More Than Pushy Tactics
  • Why Replies Are Hard to Get on BioJapan’s Partnering Platform
  • Before You Hit “Send” on That Quote — The One Move That Saves Deals in Japan

Recent Comments

No comments to show.

Archives

  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • March 2025
  • October 2024

Categories

  • Digitizing BD
  • Japan Market Entry
  • Just for fun
  • Regulatory

WeBD.Tokyo is provided through a legal entity:
Dohi Inc. (Kanagawa, Japan)
# Corporate ID: 7021001076723


Hestia | Developed by ThemeIsle